US biotechnology company Pillar Biosciences on Monday announced the launch of the oncoReveal Myeloid v2 Panel, an expanded research-use-only (RUO) DNA next-generation sequencing (NGS) panel for myeloid malignancies.

According to Pillar, the new panel expands the original oncoReveal Myeloid Panel from 58 to 80 gene targets and enhances detection of FLT3 internal tandem duplications (ITDs), including long and multiple ITDs that can be challenging for NGS assays.

Building on the original 58-gene panel, oncoReveal Myeloid v2 adds 22 genes while retaining all prior content, giving laboratories broader, guideline-relevant coverage without disrupting existing workflows. Only 4 out of the original 766 amplicons covering the original 58 genes are changed to accommodate the expansion -- a result of Pillar's proprietary SLIMamp chemistry and VersaTile primer design tool, which together enable efficient panel scaling while preserving the validated performance of existing content, Pillar said.

A key advancement in oncoReveal Myeloid v2 is the ability to accurately detect long (300+ bp) and multiple FLT3 internal tandem duplications (ITDs) with 2 x 150 sequencing, a variant class that has historically challenged short-read NGS.